Skip to main content

The PROTECT-V trial investigating UNIONs COVID-19 candidate receives Urgent Public Health Prioritization from the UK government

UNION therapeutics A/S (UNION) today announced that the National Institute for Health Research (NIHR) in the UK has granted Urgent Public Health (UPH) prioritization to the PROTECT-V trial – a platform study investigating UNION’s niclosamide-based treatment candidate for COVID-19 in kidney patients.


Union

Clinical trials granted UPH prioritization by the NIHR are deemed critically important in the fight against COVID-19 and will thus receive infrastructure support allowing expedited recruitment for the study. NIHR is an entity under the Department of Health & Social Care of the UK government.

UPH prioritization will enable streamlined site set up across the UK, and facilitate rapid patient recruitment as a result of NIHR resource and clinical research network support being available.

The PROTECT-V trial is led by the Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge and involves researchers and patients from across the UK.

For more information visit: UNION Therapeutics

Published March 29 2021

Latest from CCTU

Covid-19 treatment trial for kidney patients goes national

An Addenbrooke’s trial is rolling out to hospitals across the UK to see if a drug used to treat tapeworm can give high-risk kidney patients extra protection…

The PROTECT-V trial investigating UNIONs COVID-19 candidate receives Urgent Public Health Prioritization from the UK government

UNION therapeutics A/S (UNION) today announced that the National Institute for Health Research (NIHR) in the UK has granted Urgent Public Health (UPH)…

Trials to find preventative COVID-19 treatments for most vulnerable to launch in UK

Two new clinical trials to develop treatments to prevent people catching (coronavirus) COVID-19 are to launch in the UK.

All news